Stay updated on Rucaparib + Nivolumab in Advanced Biliary Tract Cancer Clinical Trial
Sign up to get notified when there's something new on the Rucaparib + Nivolumab in Advanced Biliary Tract Cancer Clinical Trial page.

Latest updates to the Rucaparib + Nivolumab in Advanced Biliary Tract Cancer Clinical Trial page
- Check5 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check12 days agoChange DetectedThe page has updated its treatment timeline, indicating that the average duration of treatment is now specified as 'up to 2 years' and 'average of 4 months' after starting treatment. Additionally, the revision number has been updated from v2.16.1 to v2.16.2.SummaryDifference2%
- Check20 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check27 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.2%
- Check49 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check63 days agoChange DetectedThe page has been updated to include new information about Biliary Tract Cancer and its associated study, while significant details regarding the study's inclusion and exclusion criteria have been removed.SummaryDifference32%
Stay in the know with updates to Rucaparib + Nivolumab in Advanced Biliary Tract Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Rucaparib + Nivolumab in Advanced Biliary Tract Cancer Clinical Trial page.